文献速递肿瘤 PET/CT

基于[18F]FDG PET/CT量化的代谢肿瘤负荷改善肺癌患者TNM分期

Metabolic tumor burden quantified on [18F]FDG PET/CT improves TNM staging of lung cancer patients.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-08-07

回顾性分析278例非小细胞肺癌患者的初始分期[18F]FDG PET/CT,量化全身代谢活跃肿瘤体积(MATV-WB)。MATV-WB是全因生存的独立预测因素,将MATV-WB与临床TNM分期结合的cTNM-P分期较常规cTNM分期具有更优的生存预测能力(C指数0.730 vs 0.699,p<0.001)。

要点

  • MATV-WB是全因生存的独立预测因素(p<0.001)。
  • MATV-WB≥49.5患者死亡风险为MATV-WB<49.5者的4.12倍(HR=4.12,p<0.001)。
  • cTNM-P分期较常规cTNM分期生存预测能力更优(C指数0.730 vs 0.699,p<0.001)。

核心结论

  • cTNM-P分期较常规cTNM分期具有更优的预后价值,可更好地对非小细胞肺癌患者进行分层。

研究设计与样本

  • 回顾性评估2011年1月至2016年4月间278例非小细胞肺癌患者的初始分期[18F]FDG PET/CT,并量化MATV-WB。
  • 278例中女性74例(26.6%),男性204例(73.4%);年龄34-88岁(均值±标准差:66±10)。
  • 每例患者随访时间0.7-83.6个月(均值±标准差:25.1±20.3)。

主要发现

  • MATV-WB是全因生存的独立且具统计学显著性的预测因素(p<0.001)。
  • MATV-WB的生存预测能力(C指数均值±标准差=0.7071±0.0009)不劣于cTNM(C指数均值±标准差=0.7031±0.007)(Z=-0.143,p=0.773)。
  • MATV-WB<49.5与MATV-WB≥49.5患者的估计平均生存时间分别为56.3±3.0个月(95%CI:50.40-62.23)与21.7±2.2个月(95%CI:17.34-25.98)(Log-Rank=77.48,p<0.001),1年生存率分别为86.8%与52.8%,5年生存率分别为53.6%与无生存者。
  • MATV-WB≥49.5患者死亡风险为MATV-WB<49.5者的4.12倍(HR=4.12,p<0.001)。
  • 各cTNM分期的MATV-WB截断值分别为23.7(I期)、49.5(II期)、52(III期)、48.8(IV期)(p值分别为0.029、0.227、0.025、0.001);I、III、IV期按截断值分组的估计平均全因生存时间差异有统计学显著性(p分别为0.007、0.004、<0.001),II期(p=0.365)两组间有约12个月的临床显著差异。

关键数值与推荐

  • cTNM-P分期定义:I期<23.7;I期≥23.7;II期<49.5;II期≥49.5;III期<52;III期≥52;IV期<48.8;IV期≥48.8。
  • cTNM-P分期的全因生存预测能力(C指数=0.730)优于常规cTNM分期(C指数=0.699)(Z=-4.49,p<0.001)。
  • 在所有cTNM分期中,MATV-WB≥截断值的患者生存率均较低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of our study was to test a new staging algorithm, combining clinical TNM staging (cTNM) with whole-body metabolic active tumor volume (MATV-WB), with the goal of improving prognostic ability and stratification power. METHODS: Initial staging [18F]FDG PET/CT of 278 non-small cell lung cancer (NSCLC) patients, performed between January/2011 and April/2016, 74(26.6%) women, 204(73.4%) men; aged 34-88 years (mean ± SD:66 ± 10), was retrospectively evaluated, and MATV-WB was quantified. Each patient's follow-up time was recorded: 0.7-83.6 months (mean ± SD:25.1 ± 20.3). RESULTS: MATV-WB was an independent and statistically-significant predictor of overall survival (p < 0.001). The overall survival predictive ability of MATV-WB (C index: mean ± SD = 0.7071 ± 0.0009) was not worse than cTNM (C index: mean ± SD = 0.7031 ± 0.007) (Z = -0.143, p = 0.773). Estimated mean survival times of 56.3 ± 3.0 (95%CI:50.40-62.23) and 21.7 ± 2.2 months (95%CI:17.34-25.98) (Log-Rank = 77.48, p < 0.001), one-year survival rate of 86.8% and of 52.8%, and five-year survival rate of 53.6% and no survivors, were determined, respectively, for patients with MATV-WB < 49.5 and MATV-WB ≥ 49.5. Patients with MATV-WB ≥ 49.5 had a mortality risk 2.9-5.8 times higher than those with MATV-WB < 49.5 (HR = 4.12, p < 0.001). MATV-WB cutoff points were also determined for each cTNM stage: 23.7(I), 49.5(II), 52(III), 48.8(IV) (p = 0.029, p = 0.227, p = 0.025 and p = 0.001, respectively). At stages I, III and IV there was a statistically-significant difference in the estimated mean overall survival time between groups of patients defined by the cutoff points (p = 0.007, p = 0.004 and p < 0.001, respectively). At stage II (p = 0.365), there was a clinically-significant difference of about 12 months between the groups. In all cTNM stages, patients with MATV-WB ≥ cutoff points had lower survival rates. Combined clinical TNM-PET staging (cTNM-P) was then tested: Stage I < 23.7; Stage I ≥ 23.7; Stage II < 49.5; Stage II ≥ 49.5; Stage III < 52; Stage III ≥ 52; Stage IV < 48.8; Stage IV ≥ 48.8. cTNM-P staging presented a superior overall survival predictive ability (C index = 0.730) compared with conventional cTNM staging (C index = 0.699) (Z = -4.49, p < 0.001). CONCLUSION: cTNM-P staging has superior prognostic value compared with conventional cTNM staging, and allows better stratification of NSCLC patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lapa P, Oliveiros B, Marques M, et al. Metabolic tumor burden quantified on [18F]FDG PET/CT improves TNM staging of lung cancer patients. Eur J Nucl Med Mol Imaging. 2017. PMID: 28785842. doi:10.1007/s00259-017-3789-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。